Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib adjuvant phase II study in FGFR3-altered high-risk urothelial carcinoma after radical surgery
2019-001833-14Phase 2Terminated
- Sponsor
- EAU Research Foundation
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemigatinib in transitional cell carcinoma (TCC), transitional cell carcinoma of the bladder (TCC) and upper tract urothelial carcinoma (UTUC), sponsored by EAU Research Foundation. Primary endpoint: 2-year relapse-free survival rate. Started Sep 2020; status: terminated.
02
Drugs
pemigatinib
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2019-001833-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001833-14.